Amgen Inc

Jump to

Amgen to buy Celgene's psoriasis drug Otezla for $13.4 billion in cash

The deal for Otezla and certain related assets and liabilities is valued at $11.2 billion, net of the present value of $2.2 billion in future cash tax benefits.
Syngene Q2 net up 54% at Rs 75 crore

Biocon's contract research arm Syngene International today posted 54.02 per cent rise in its net profit at Rs 74.7 crore for the second quarter ended September 30, driven by discovery and R&D centre business verticals.
More investor activism expected, but returns likely lower

Activist investing is a rarefied field with only 71 of the world's roughly 10,000 hedge funds pursuing strategies in which managers push corporations to boost financial performance, spin off divisions, or improve corporate governance.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Amgen Inc

Amgen to buy Celgene's psoriasis drug Otezla for $13.4 billion in cash

Syngene Q2 net up 54% at Rs 75 crore

More investor activism expected, but returns likely lower